Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 4, 2010

View Archived Issues

Preclinical studies reveal potential of KX-01 for treatment of breast cancer

Recommended phase I dose of breast cancer candidate SR-16157 determined

Biodel submits NDA to FDA for VIAject for treatment of diabetes

Nature's Products acquires Nutrition 21's direct response and retail businesses

Pfizer provides U.S. regulatory update on Prevnar 13 vaccine

QLT acquires Othera's OT-730 for glaucoma

DAS-181 enters phase II of clinical development for influenza

ORE-1001 enters phase I/II trials in ulcerative colitis

Eli Lilly moves LY-2525623 into phase II for psoriasis

Merck & Co.'s MK-8266 enters phase I testing for the first time

Anesiva unable to complete merger with Arcion Therapeutics and files for bankruptcy

Donepezil evaluated in first large study of pharmacological treatment of Down syndrome

IGF-I receptor inhibitor PQIP enhances doxorubicin cytotoxicity in human cancer cell lines

Evolva and Roche sign drug discovery agreement in oncology and anti-infectives

Millennium's TAK-285 may have potential to treat brain metastases from breast cancer

Novartis to acquire Alcon through agreement with Nestle

Photocure presents update on Hexvix NDA for detection of bladder cancer

D-Pharm initiates enrollment in Israel into phase III trial of DP-b99 in acute ischemic stroke

Stryker acquires Ascent

ADA presents new guidelines for use of the A1C test for diabetes

Teijin Pharma presents cathepsin K inhibitors for osteoporosis

Janssen presents novel tubulin polymerization inhibitors for cancer therapy

Novel monoamine reuptake inhibitors described by Takeda as anxiolytics

Janssen discloses leukotriene A-4 hydrolase inhibitors for treatment of asthma

Eisai presents new antagonists of corticotropin-releasing factor receptor 1 as anxiolytics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for July 7, 2025.
House passes H.R. 1, restoring R&D tax cuts
BioWorld MedTech
The House of Representatives passed H.R. 1, also known as One Big Beautiful Bill, which will restore personal income tax cuts that expired in 2022. However, the...
With surface mimicry, molecular glues shed hairpin need
BioWorld Science
Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
Exercise-mimicking compound offers alternative to GLP-1 therapies
BioWorld
An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...